- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01407835
Biological Standardization of Dactylis Glomerata Allergen Extract
Biological Standardization of Dactylis Glomerata Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units
Study Overview
Status
Conditions
Detailed Description
This is an open, unblinded and non-randomized biological assay. The study design is a slight modification of the recommendations proposed by the Nordic Guidelines.
Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Madrid / Madrid
-
Madrid, Madrid / Madrid, Spain, 28005
- Hospital Universitario La Princesa
-
-
Sevilla / Andalucía
-
Sevilla, Sevilla / Andalucía, Spain, 41700
- Hospital El Tomillar - Area Hospitalaria de Valme
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A documented positive case history with inhalation allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) related to Dactylis glomerata.
- Subject has provided written informed consent, appropriately signed and dated by the subject (or legal representative, if applicable).
- Subject can be male or female of any race and ethnic group.
- Age > 18 years and < 50 years at the study inclusion day.
- Positive skin prick test with a standardized commercially available preparation of Dactylis glomerata allergen extract. The skin prick test will be considered positive if the test results in a wheal major diameter of at least 3 mm and at least the size of the positive control. Positive skin prick test results are valid if performed within one year prior to the inclusion of the subject in the study
- A positive test for specific IgE to Dactylis glomerata(CAP-RAST ≥ 2). IgE results are valid if performed within one year prior to the inclusion of the subject in the study.
- Allergic symptoms during the pollen season of Dactylis glomerata.
- Mean of the forearm major diameters of the wheals provoked by histamine dihydrochloride (10 mg/ml) ≥ 3 mm.
Exclusion Criteria:
- Immunotherapy in the past 5 years with an allergen preparation known to interfere with the allergen to be tested (e.g., grass group extracts).
- Use of drugs that may interfere with the skin reactions (e.g., antihistamines). See Appendix 1
- Treatment with any of the following medications: tricyclic or tetracyclic antidepressants, β-blockers or corticosteroids (> 10 mg/day of prednisone or equivalent).
- Pregnancy.
- Dermographism affecting the skin area at the test site at either study visit.
- Atopic dermatitis affecting the skin area at the test site at either study visit.
- Urticaria affecting the skin area at the test site at either study visit.
- Participation in another clinical trial within the last month.
- Subjects suffering from pathologies or conditions in which adrenalin is contraindicated (heart disease, severe hypertension,..)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase.
Time Frame: Test sites should be inspected and recorded 15-20 min after application
|
Test sites should be inspected and recorded 15-20 min after application
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 6038-PR-PRI-181
- 2010-023948-33 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergy to Grass Pollen (Dactylis Glomerata)
-
Laboratorios Leti, S.L.Completed
-
Laboratorios Leti, S.L.Completed
-
Laboratorios Leti, S.L.CompletedAllergy to Grass Pollen (Secale Cereale)Spain
-
Aston UniversityNational Pollen and Aerobiology Unit, WorcesterCompletedGrass Pollen Ocular AllergyUnited Kingdom
-
University of ZurichAlleCureCompletedRhinoconjunctivitis Due to Grass Pollen AllergySwitzerland
-
MacroArray Diagnostics GmbHCompletedCat Allergy | Grass Pollen Allergy | Birch Pollen Allergy | House Dust Mite Allergy | Bee Venom Allergy | Vespid Venom AllergyAustria
-
Laboratorios Leti, S.L.Completed
-
Biomay AGCompletedGrass Pollen AllergyAustria, Belgium, Denmark, Germany, Netherlands, Slovenia
-
Biomay AGCompletedGrass Pollen AllergyAustria
-
Allergopharma GmbH & Co. KGCompletedGrass Pollen AllergyGermany
Clinical Trials on Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control
-
Laboratorios Leti, S.L.Completed
-
Laboratorios Leti, S.L.CompletedAllergy to Grass Pollen (Secale Cereale)Spain
-
Laboratorios Leti, S.L.Completed
-
Laboratorios Leti, S.L.Completed
-
Laboratorios Leti, S.L.CompletedAllergy to Alternaria FungusSpain
-
Johns Hopkins UniversityCompleted
-
Aravena, Pedro, DDS, PhDUniversidad Austral de ChileCompleted
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN); Tunitas Therapeutics, Inc.Terminated
-
GlaxoSmithKlineCompletedDental PlaqueUnited Kingdom
-
Procter and GambleCompleted